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Dr.Nissen’s comments [1] onour paper [2]
reveal a fundamental difference in his and
our perspectives on the ethical conduct of
clinical trials. While we agree with his
central point that the ADAPT data do not
permit deﬁnitive conclusions regarding
the safety of naproxen or celecoxib, we
doubt Dr. Nissen’s conjecture that the
ADAPT safety data could—or should—
have been more interpretable had a
different model of data review been
applied to adverse events.
Safety data in ADAPT, as in most trials,
were not collected to test hypotheses.
Instead, they were collected to protect
trial subjects from harm to the extent
possible, and to ensure that the
investigators and the funding agency
fulﬁlled their important obligations on
this point. Stopping a trial for beneﬁt and
stopping to avoid harm are, fortunately,
not symmetrical occurrences: typically
one stops to avoid harm when inference is
far less certain than would be required to
afﬁrm beneﬁt. This principle—a direct
reﬂection of the trial investigator’s ethical
obligations to study participants—was
especially important for ADAPT, a
primary prevention trial with 7–10 years
of planned interventions and no
anticipated short-term beneﬁts. For the
same reason, the stopping rules
mentioned by Dr. Nissen are typically
applied to prevent a premature
conclusion of beneﬁt, not of harm.
To clarify, it was the ADAPT Steering
Committee, and not the National
Institutes of Health (NIH), that bore
ultimate responsibility for the decision to
suspend the ADAPT treatments. The
suspension of celecoxib was a direct
consequence of Pﬁzer’s announcement
on December 17, 2004, of termination of
the APC and PreSAP trials, citing
cardiovascular risks with celecoxib [3]
even though, as our paper shows, the
ADAPT data suggested little
cardiovascular risk with celecoxib [2].
The decision to suspend treatment
with naproxen was more difﬁcult. As we
told the Food and Drug Administration
(FDA) Advisory Committee [4], the safety
data ‘‘.... would not in themselves have
led to a decision to suspend either
treatment...[because of any] conclusion
that this signal [with naproxen]
was...sufﬁciently compelling or deﬁnitive
to warrant a recommendation to suspend
the treatment.’’ Yet, several operational
issues would have made continuation of
the naproxen arm difﬁcult. These
included a necessity to obtain revised
consent from participants—hence, review
of new consent forms by seven
Institutional Review Boards—as well as a
reluctance to imply, by continuing
naproxen, that it was ‘‘safe’’ while
celecoxib was not.
Both decisions were taken in
consultation with the Chair of the trial’s
data monitoring committee and with
program staff of the National Institute on
Aging. But in any event, on December 23,
six days later, the FDA put a Full Clinical
Hold on ADAPT and other primary
prevention trials that administered
celecoxib. The procedures required for
reinstatement of the ADAPT
investigational new drug (IND)
application would have taken months,
and in the interim all treatments would
have been suspended regardless of our
earlier decision.
We concur with Dr. Nissen,
nonetheless, about the lamentable and
somewhat misleading publicity that
surrounded our decision. On December
20, 2004, the NIH Director’s ofﬁce
reviewed the preliminary ADAPT
cardiovascular safety results and
forwarded them to the leadership of the
FDA. The NIH Deputy Director then
convened a conference call with the
ADAPT Study Chair (JCSB) and Director
of the Coordinating Center (CLM) to
announce that a press teleconference
would be held in cooperation with the
FDA later that day. While that press
conference was in process, the Director’s
ofﬁce issued the press release referenced
by Dr. Nissen, after which the ADAPT
Study Chair was asked to answer several
reporters’ questions. The ensuing press
coverage is well summarizedby Dr. Nissen.
We also lament the long delay in
publication of the ADAPT cardiovascular
safety results. In fact, with full
acknowledgement of their limitations, we
had submitted these results to no fewer
than ﬁve other journals before they were
accepted by PLoS Clinical Trials.
Consistently, the reason for rejection was
that the data were ‘‘not deﬁnitive’’ (as we
had acknowledged) or that results ran
counter to expectation. Notwithstanding
the logistical difﬁculties cited, we were
surprised to learn of the other journals’
evident view that publication of the
ADAPT safety results would have been
justiﬁed only if the treatments had been
continued until there was a clear
demonstration of harm with naproxen.
We remain resolute in our convictions
on the following principles:
1. Ultimately, it is the investigators who
are responsible for the well-being of those
studied in trials. They report to
Institutional Review Boards; data
monitoring committees do not.
2. One does not do trials to ﬁnd
‘‘signiﬁcant’’ or ‘‘deﬁnitive’’ evidence of
harm, especially in long-term prevention
trials with healthy people. The risk–
beneﬁt balance in such trials is especially
vulnerable to unforeseen situations such
asaroseforADAPTonDecember17,2004.
3. Before blaming anyone for the
decision to suspend treatments in ADAPT,
one should consider the ‘‘mother test.’’
Given what is now known, would you have
advised your aging mother to remain a
participant receiving treatments in
ADAPT? No member of the ADAPT
leadershipcouldanswerthisquestion‘‘yes.’’
4. While almost all will agree that some
data—especially those from a randomized
experiment unlikely to be repeated—are
betterthan none,mostjournal editorsand
reviewers seem paradoxically to prefer
‘‘signiﬁcant’’ or ‘‘deﬁnitive’’ untoward
results. We think this is unfortunate. We
agree that these data should have been
published long ago. We are grateful to the
editors of PLoS Clinical Trials for taking us
at our word and publishing them. “
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